您好,欢迎来到化工原料网! [登录] [免费注册]
化工原料网
位置:首页 > 产品库 > BC 11-38
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
BC 11-38
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
BC 11-38图片
CAS NO:686770-80-9
规格:98%
分子量:304.43
包装与价格:
包装价格(元)
5mg电议
10mg电议
25mg电议

产品介绍
Selective PDE11 inhibitor
CAS:686770-80-9
分子式:C15H16N2OS2
分子量:304.43
纯度:98%
存储:Store at -20°C

Background:

BC 11-38 is a selective inhibitor of PDE11 with an IC50 value of 0.28 μM [1].


PDE11 is a PDE family. In humans the PDE11A gene encodes four isoforms hydrolyzing both cAMP and cGMP. PDE11A is expressed in skeletal muscle, brain, prostate, testis, kidney, pancreas, liver, lymphoid cells, and pituitary and adrenal glands [2].


In H295R human adenocarcinoma cells, BC11-38 significantly increased cortisol production and cAMP levels, both in the presence and absence of the adenylate cyclase activator forskolin. In H295R cells, BC11-38 elevated ATF-1 phosphorylation in a manner that corresponded with its potency against PDE11. In several lines including MDA-MB-231 and HeLa cells, there were very low levels of PDE11A mRNA. In MDA-MB-231 cells, BC11-38 failed to elevate cAMP levels and CREB phosphorylation. In HeLa cells, BC11-38 did not affect cAMP levels or CREB phosphorylation [2]. In p54nrb/NONOKD cells, combining treatment with BC11-38 and ACTH restored partially the capacity to produce DHEA and cortisol in response to cAMP stimulation and the ability to generate cAMP in response to ACTH stimulation [3].


An invention also relates to the use of compounds such as BC11-38 to elevate cortisol levels in a subject who has adrenal suppression, e.g. where a subject is being administered with a corticosteroid, or on a long-term corticosteroid treatment [4].


参考文献:
[1].  Cichero E, D'Ursi P, Moscatelli M, et al. Homology modeling, docking studies and molecular dynamic simulations using graphical processing unit architecture to probe the type-11 phosphodiesterase catalytic site: a computational approach for the rational design of selective inhibitors. Chemical biology & drug design, 2013, 82(6): 718-731.
[2].  Ceyhan O, Birsoy K, Hoffman CS. Identification of biologically active PDE11-selective inhibitors using a yeast-based high-throughput screen. Chemistry & biology, 2012, 19(1): 155-163.
[3].  Lu JY, Sewer MB. p54nrb/NONO Regulates Cyclic AMP-Dependent Glucocorticoid Production by Modulating Phosphodiesterase mRNA Splicing and Degradation. Molecular and cellular biology, 2015, 35(7): 1223-1237.
[4].  Hoffman CS, Ceyhan O. Inhibitors of phosphodiesterase 11 (PDE11): U.S. Patent 9,173,884[P]. 2015-11-3.